Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein
Viruses · 2025
DOI: 10.3390/v17040476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Debora Patricia Garanzini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Agrobiotecnología y Biología Molecular (IABiMo), Instituto Nacional de Tecnología Agropecuaria (INTA), Consejo Nacional de Investigacion…. Hauptthemen laut MEDLINE: Rabies, Rabies Vaccines, Genetic Vectors, Rabies virus. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Agricultural Technology Institute, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Instituto Nacional de Tecnología Agropecuaria (INTA).
Abstract (Originalsprache)
Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Agrobiotecnología y Biología Molecular (IABiMo), Instituto Nacional de Tecnología Agropecuaria (INTA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nicolás Repetto y De Los Reseros…
- Servicio de Vacuna Antirrábica (SVAR), Instituto Nacional de Producción de Biológicos, ANLIS-"Dr. Carlos G. Malbrán", Av. Vélez Sarsfield 563, Ciudad Autónoma de Buenos Aires C1282AFF, Argentina.
ORCID-Profile: Debora Patricia Garanzini, Matias Ariel Micucci, Gabriela Calamante, Maria Paula Del Medico Zajac
Förderung
- National Agricultural Technology Institute
- Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
- Instituto Nacional de Tecnología Agropecuaria (INTA)
- Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)
Zitieren
APA
Garanzini, D. P., Micucci, M. A., Torres Lopez, A., Perez, O., Calamante, G., & Del Medico Zajac, M. P. (2025). Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein. Viruses. https://doi.org/10.3390/v17040476
Vancouver
Garanzini DP, Micucci MA, Torres Lopez A, Perez O, Calamante G, Del Medico Zajac MP. Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein. Viruses. 2025. doi:10.3390/v17040476
BibTeX
@article{Garanzini2025,
author = {Garanzini, Debora Patricia and Micucci, Matias Ariel and Torres Lopez, Annalies and Perez, Oscar and Calamante, Gabriela and Del Medico Zajac, Maria Paula},
title = {Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17040476}
}
EUVIMED